Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

About KB801 KB801 is a redosable eye drop gene therapy designed to enable sustained, localized expression and secretion of nerve growth factor (NGF) by epithelial cells in the front of the eye for the ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

KB801 is a redosable eye drop gene therapy in development for the treatment of NK, a degenerative corneal disease characterized by damage or loss of function in the neurons innervating the eye ...

Additional exploratory efficacy measures will include change in corneal lesion size from baseline, each assessed at weeks 4, 6, 8, 10, and 20, as well as evaluations of corneal sensation and ...

Helicobacter pylori, best known for causing stomach ulcers, was shown to block the build-up of both amyloid-beta and tau in our study.

Peptic ulcers may be less common, but their risks—and treatments—are evolving rapidly. Learn about symptoms, causes like H. pylori and NSAIDs, & new therapies.

In addition to aniridia and neurotrophic keratopathy, RESTORE VISION is studying five other rare diseases affecting the ocular surface: ocular cicatricial pemphigoid, an autoimmune disease that ...

Advances in corneal healing research drive new treatments for rare eye diseases Scientists have identified key corneal neurons involved in sensitivity and developed an experimental model to study ...